Targeted therapy of cancer: new roles for pathologists—prostate cancer

Rubin, Mark A.

doi:10.1038/modpathol.2008.11

Cited by 46 publications

(33 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is vital to identify more genes that are specifically linked to PCA, so that we may expand our understanding of this disease and assist in the development of new diagnostic indicators and new targets for therapy. 1 NDRG was initially discovered overexpressing in N-myc knockout mice. Accordingly, it was named the 'N-myc downstream-regulated gene'.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma

Chen¹,

Dang³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma

Chen¹,

Dang³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…cancer biomarker | peptide library | prostate cancer | phage display P rostate cancer accounts for nearly 27,000 deaths annually, with end-stage bone metastases representing a leading cause of morbidity and mortality (1). The introduction of diagnostic serum biomarkers into clinical practice, such as prostate-specific antigen (PSA), has greatly improved early detection of the disease (2).…”

mentioning

confidence: 99%

Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer

Mintz¹,

Rietz

Cardó-Vila

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

In response to an urgent need for improved diagnostic and predictive serum biomarkers for management of metastatic prostate cancer, we used phage display fingerprinting to analyze sequentially acquired serum samples from a patient with advancing prostate cancer. We identified a peptide ligand, CTFAGSSC, demonstrating an increased recovery frequency over time. Serum antibody reactivity to this peptide epitope increased in the index patient, in parallel with development of deteriorating symptoms. The antigen mimicking the peptide epitope was identified as alpha-2-HeremansSchmid glycoprotein, also known as fetuin-A. Metastatic prostate cancer cell lines and bone metastasis samples displayed robust fetuin-A expression, and we demonstrated serum immune reactivity to fetuin-A with concomitant development of metastatic castrateresistant disease in a large cohort of prostate cancer patients. Whereas fetuin-A is an established tumor antigen in several types of cancer, including breast cancer, glioblastoma, and pancreas cancer, this report is to our knowledge the first study implicating fetuin-A in prostate cancer and indicating that autoantibodies specific for fetuin-A show utility as a prognostic indicator for prostate cancer patients prone to progress to metastatic disease.cancer biomarker | peptide library | prostate cancer | phage display

show abstract

“…(7)(8)(9)(10)(11) Tumor stroma consists of activated fibroblasts (myofibroblasts) and smooth muscle, endothelial and inflammatory cells, including macrophages. Macrophages that migrate to tumor stroma are called tumor-associated macrophages (TAM).…”

mentioning

confidence: 99%

Interaction of coagulation factors and tumor‐associated macrophages mediates migration and invasion of gastric cancer

Ma¹,

He²,

Wang³

et al. 2010

Cancer Science

View full text Add to dashboard Cite

Abundant macrophage infiltration and increased expression of coagulation factors have been observed in cancer patients. The aim of the present study was to determine how the interaction between activated coagulation factors and monocytes/macrophages contributes to gastric cancer (GC) cell migration and invasion. We assessed cytokine/chemokine production of coagulationfactor-treated macrophages by ELISA. The effects of the interaction between coagulation factors and tumor-associated macrophages (TAM) on GC cell migration and invasion were determined by in vitro migration and invasion assay. In addition, we used an in vitro co-culture system of GC cells/TAM treated by coagulation factors to evaluate the effect of coagulation factor/TAM interaction on the human umbilical vein endothelial cell line (HUVEC). We found that the M2-like phenotype of interleukin (IL)-4 high , IL-10 high , transforming growth factor (TGF)-b high , tumor necrosis factor (TNF)-a high was exhibited when the human monocytic cell line THP-1 was stimulated by coagulation factors III (TF), VIIa (FVIIa) and XIIa (FXIIa). For the migration assay, the GC cells (BGC-823 or SGC-7901) that were co-cultured with activated coagulation factor/ TAM both showed increased migration. For the invasion assay, both BGC-823 and SGC-7901 cells co-cultured with TF/TAM showed increased invasion. We also found that TAM activated by coagulation factors could induce vascular endothelial growth factor/MMP-9 expression, which could promote invasion of GC cells. The HUVEC co-cultured with TAM (PMA-treated THP-1 macrophages co-cultured with GC cells) expressed high levels of FXIIa. In conclusion, coagulation factors might facilitate GC cell migration and invasion by transforming macrophages toward TAM-like cells. Interaction of coagulation factors and TAM mediates migration and invasion of GC. (Cancer Sci 2011; 102: 336-342) D espite its decreasing incidence, gastric cancer (GC) is still the second leading cause of cancer-related death worldwide, particularly in Asian countries.(1) Peritoneal metastasis is the most frequent event in recurrent GC and occurs in 34% of patients with recurrence, even after curative resection of the primary tumor.(2) Therefore, new approaches to the treatment of metastatic GC have become a hot topic. In addition to clonal selection and the predetermined metastatic potential of cancer cells, there is increasing evidence that the microenvironment modifies cancer cell metastasis.(3-6) Thus, one approach to the treatment of metastatic GC is to identify novel targets based on cancer cell-tumor microenvironment interactions. (7)(8)(9)(10)(11) Tumor stroma consists of activated fibroblasts (myofibroblasts) and smooth muscle, endothelial and inflammatory cells, including macrophages. Macrophages that migrate to tumor stroma are called tumor-associated macrophages (TAM). The role of TAM in tumor progression is complicated. Although activated macrophages might have antitumor activity, tumor cells are reported to escape the antitumor activity of TAM.(...

show abstract

Targeted therapy of cancer: new roles for pathologists—prostate cancer

Cited by 46 publications

References 83 publications

Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma

Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma

Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer

Interaction of coagulation factors and tumor‐associated macrophages mediates migration and invasion of gastric cancer

Contact Info

Product

Resources

About